Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Bristol Myers Squibb - Integration of immuno-oncology into the perioperative MIUC treatment landscape

Q&A

Date

04 Dec 2022

Session

Bristol Myers Squibb - Integration of immuno-oncology into the perioperative MIUC treatment landscape

Topics

Immunotherapy

Tumour Site

Urothelial Cancer

Presenters

Laurence Albiges

Authors

L. Albiges

Author affiliations

  • Medical Oncology Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.